http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 24 Jul 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Insight+Molecular+Diagno+++++++++++++/26813565.html si-local-file:///var/storage/secattach/20260724/26813565.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Insight+Molecular+Diagno+++++++++++++/26813565.html Fri, 24 Jul 2026 16:06:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Insight+Molecular+Diagno+++++++++++++/26813565.html si-local-file:///var/storage/secattach/20260724/26813565.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Insight+Molecular+Diagno+++++++++++++/26813565.html Fri, 24 Jul 2026 16:06:00 -0400 IMDX O.07511324 http://www.streetinsider.com/Corporate+News/iMDx+kidney+transplant+test+featured+in+Lancet+study%2C+gets+Medicare+nod/26805005.html <p>Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) highlighted a study published in <em>The Lancet Regional Health – Europe</em> that examined the use of its GraftAssure donor-derived cell-free DNA (dd-cfDNA) testing technology to guide treatment decisions for kidney transplant patients experiencing antibody-mediated rejection (AMR).</p><p>The study is an extension of a Phase 2 felzartamab trial published in the <em>New England Journal of Medicine</em> in 2024, which also used GraftAssure testing. In that earlier study, researchers reported that CD38-targeted therapy may offer an approach to treating AMR, and that dd-cfDNA testing helped demonstrate therapeutic efficacy. Clinicians subsequently continued monitoring patients using GraftAssure to detect http://www.streetinsider.com/Corporate+News/iMDx+kidney+transplant+test+featured+in+Lancet+study%2C+gets+Medicare+nod/26805005.html Thu, 23 Jul 2026 08:04:19 -0400 IMDX http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Press+Releases/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html <ul type="disc"><li style="margin-bottom:8pt;">Study published by Lancet Regional Health helps doctors manage new class of drugs for kidney transplant patients suffering organ rejection</li><li style="margin-bottom:8pt;">Serial monitoring of patients through donor-derived cell-free DNA (dd-cfDNA) testing helps to guide treatment decisions</li><li style="margin-bottom:8pt;">New study signals GraftAssure™ assay’s market expansion opportunity as drugs to treat organ rejection work their way through clinical trials</li><li style="margin-bottom:8pt;">iMDx has received confirmation of Medicare reimbursement coverage for treatment response monitoring with dd-cfDNA testing</li></ul> <p>NASHVILLE, Tenn., July 23, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (&quot;iMDx&quot;) today highlighted the publication of a <a target="_blank" href="https://www.globenewswire.com/Tracker?data=vUr_NMmjjYsYWeI6kgYLmp8a20Hgs4laG14H36wLTB3o4JWU2MWRmIGXJ19simmkbkGO45INAHlOqxfUDjoJbT9ylyjSMFbs_Kemlm-zcCs2Jgta-M5oOspIQbTXVz_GYI1ZFmg5zXSzvgJ9-kUckXHEyxg1i2WOuvyt3qWohSrTAzzEceqBW8UjkJK-9vMfwmQ8iDzdg5h61Xzudkpt0g==" rel="nofollow" target="_blank">new study http://www.streetinsider.com/Globe+Newswire/iMDx+GraftAssure+Assay+Guides+Use+of+Potentially+Kidney-Graft-Saving+Drug+in+New+Lancet+Group+Publication/26804800.html Thu, 23 Jul 2026 08:00:00 -0400 A.06822034 A.28005717 IMDX O.07511324 O.20020231 O.20026344 http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Press+Releases/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html <ul><li>Industry-wide coverage policy expands reimbursement framework for donor-derived cell-free DNA testing</li><li>Supports iMDx&apos;s commercial strategy in transplant monitoring</li><li style="margin-bottom:8pt;">Final policy establishes recurring testing baseline opportunity, providing reimbursement clarity on surveillance testing for hospitals, physicians, and laboratories</li><li style="margin-bottom:8pt;">Final policy cites iMDx-affiliated research, affirming iMDx’s scientific leadership in the industry</li></ul> <p>NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today highlighted a favorable new Medicare policy supporting expanded coverage for donor-derived cell-free DNA (dd-cfDNA) testing in transplant care.</p> <p>The company believes the updated policy, known as a local coverage http://www.streetinsider.com/Globe+Newswire/Favorable+Medicare+Coverage+Decision+Supports+Commercial+Adoption+of+iMDx+GraftAssure+Assay+Portfolio/26779367.html Thu, 16 Jul 2026 15:22:00 -0400 A.28005717 IMDX O.07511324 O.20020231 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Insight+Molecular+Diagno++For%3A+Jul+01++Filed+by%3A+SILVERMAN+LOU/26737168.html si-local-file:///var/storage/secattach/20260706/26737168.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Insight+Molecular+Diagno++For%3A+Jul+01++Filed+by%3A+SILVERMAN+LOU/26737168.html Mon, 06 Jul 2026 20:40:00 -0400 IMDX O.07511324 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Insight+Molecular+Diagno++For%3A+Jul+01++Filed+by%3A+SILVERMAN+LOU/26737168.html si-local-file:///var/storage/secattach/20260706/26737168.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Insight+Molecular+Diagno++For%3A+Jul+01++Filed+by%3A+SILVERMAN+LOU/26737168.html Mon, 06 Jul 2026 20:40:00 -0400 IMDX O.07511324